What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
The scientist’s investigation covers issues in Internal medicine, Surgery, Immunology, Oncology and Leukemia.
His research combines Gastroenterology and Internal medicine.
His study focuses on the intersection of Surgery and fields such as Hazard ratio with connections in the field of Intention-to-treat analysis.
In his research on the topic of Immunology, Bronchoalveolar lavage, Pulmonary alveolus and Granulocyte macrophage colony-stimulating factor is strongly related with Pulmonary alveolar proteinosis.
His Oncology research is multidisciplinary, incorporating elements of B-cell lymphoma, Mantle cell lymphoma, Clinical trial and Diffuse large B-cell lymphoma.
His Leukemia research integrates issues from Cancer research, Myeloid leukemia, Imatinib, Imatinib mesylate and Pharmacology.
His most cited work include:
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study (1802 citations)
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets (1694 citations)
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets (1694 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Oncology, Surgery, Rituximab and Lymphoma are his primary areas of study.
His studies deal with areas such as Gastroenterology and Immunology as well as Internal medicine.
He combines subjects such as Mantle cell lymphoma, Clinical trial and Fludarabine with his study of Oncology.
The study incorporates disciplines such as Salvage therapy, Follicular lymphoma and Progression-free survival in addition to Rituximab.
His Lymphoma study incorporates themes from Cancer and Radiology.
His Venetoclax research incorporates elements of Relapsed refractory, Ibrutinib and Minimal residual disease.
He most often published in these fields:
- Internal medicine (87.68%)
- Oncology (44.00%)
- Surgery (29.04%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (87.68%)
- Oncology (44.00%)
- Venetoclax (25.19%)
In recent papers he was focusing on the following fields of study:
John F. Seymour mainly investigates Internal medicine, Oncology, Venetoclax, Chronic lymphocytic leukemia and Rituximab.
Many of his research projects under Internal medicine are closely connected to In patient with In patient, tying the diverse disciplines of science together.
His studies in Oncology integrate themes in fields like Clinical trial, Obinutuzumab, Diffuse large B-cell lymphoma, Follicular lymphoma and Myeloid leukemia.
His Venetoclax research includes themes of Cancer research, Mantle cell lymphoma, Ibrutinib, Relapsed refractory and Fludarabine.
The Chronic lymphocytic leukemia study combines topics in areas such as Hematopoietic stem cell transplantation, Neutropenia and Tumor lysis syndrome.
His Rituximab study combines topics from a wide range of disciplines, such as Gastroenterology, Progression-free survival and Combination therapy.
Between 2016 and 2021, his most popular works were:
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL (392 citations)
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (350 citations)
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (350 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Disease
His scientific interests lie mostly in Internal medicine, Venetoclax, Oncology, Chronic lymphocytic leukemia and Rituximab.
His work on Internal medicine is being expanded to include thematically relevant topics such as Gastroenterology.
John F. Seymour combines subjects such as Progressive disease, Cancer research, Neoplasm, Ibrutinib and Minimal residual disease with his study of Venetoclax.
His Induction chemotherapy study, which is part of a larger body of work in Oncology, is frequently linked to Azacitidine, bridging the gap between disciplines.
His research integrates issues of Bruton's tyrosine kinase, Fludarabine and Tumor lysis syndrome in his study of Chronic lymphocytic leukemia.
The study incorporates disciplines such as Neutropenia, Salvage therapy, Surgery and Cumulative incidence in addition to Rituximab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
